ClinicalTrials.gg
CompletedNCT03817853Updated Apr 4, 2024Results posted

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

A Phase 4 interventional study of Obinutuzumab and Bendamustine in Advanced Follicular Lymphoma, sponsored by Hoffmann-La Roche. Completed at 33 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
114
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing obinutuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 1 of them phase 3. obinutuzumab · Lymphoma, Follicular.

Enrollment
6th of 30
114 · median 49
Started
2019
with 2 others
Phase 4
Only one
of the 30
Registered
16th of 30
by date
Lead sponsor
3 of 30
Hoffmann-La Roche

Among the 30 studies testing obinutuzumab in Lymphoma, Follicular, this one is the 6th largest by enrollment, is one of 3 that started in 2019, is the only one in phase 4, and was the 16th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 30 studies testing obinutuzumab in Lymphoma, Follicular are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing obinutuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in participants with previously untreated advanced follicular lymphoma (FL). The study has two phases: in the first phase, participants will receive the first cycle of obinutuzumab-based chemotherapy (G-chemo) induction therapy as usual with the first three infusions of obinutuzumab (1000 mg) administered at the regular infusion rate on Day 1, 8, and 15 of cycle 1. Phase 2 starts when participants who do not experience any Grade ≥ 3 infusion related reactions during the first cycle receive their first obintuzumab infusion given at the faster infusion rate in Cycle 2. For Cycle 2, Day 1 and all other following infusions (including maintenance), obinutuzumab will be administered at a faster infusion of 90-minute SDI, as long as the participant does not experience any Grade ≥ 3 infusion related reactions. The investigator is free to choose the chemotherapy for each participant (bendamustine, CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone/methylprednisolone], or CVP [cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone]). The total number of cycles of G-chemo induction therapy and the cycles length depends on the chemotherapy chosen for each participant.

03

Conditions studied

  • Advanced Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with previously untreated Stage III or IV FL or Stage II bulky disease scheduled to receive obinutuzumab plus chemotherapy due to at least one of the following criteria: a.) Bulky disease, defined as a nodal or extranodal (except spleen) mass

    ≥ 7 cm in the greatest diameter b.) Local symptoms or compromise of normal organ function due to progressive nodal disease or extranodal tumor mass c.) Presence of B symptoms (fever [> 38ºC], drenching night sweats, or unintentional weight loss of > 10% of normal body weight over a period of 6 months or less) d.) Presence of symptomatic extranodal disease (e.g., pleural effusions, peritoneal ascites) e.) Cytopenias due to underlying lymphoma (i.e., \< 1.0 × 109/L, \< 10 g/dL, and/or count \< 100 × 109/L) f.) Involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3 cm g.) Symptomatic splenic enlargement

  • documented CD-20-positive FL, as determined by the local laboratory
  • (ECOG) performance status 0-2
  • Adequate hematologic function (unless abnormalities are related to FL)
  • of ≥ 12 months
  • For women who are not (≥ 12 consecutive months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \< 1% per year during the treatment period and for at least 18 months after the last dose of obinutuzumab, for at least 3 months after the last dose of bendamustine or according to institutional guidelines for CHOP or CVP chemotherapy, whichever is longer
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • FL
  • Prior treatment for FL with chemotherapy, radiotherapy, or immunotherapy
  • Grade IIIb FL
  • Histological evidence of transformation of FL into high-grade B-cell NHL
  • Treatment with systemic medications, including, but not limited to, prednisone/prednisolone/methylprednisolone (at a dose equivalent to >30 mg/day prednisone), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1
  • History of solid organ transplantation
  • History of anti-CD20 antibody therapy
  • History of severe allergic or anaphylactic reaction to humanized, chimeric, or murine monoclonal antibodies
  • Known sensitivity or allergy to murine products
  • Known to biopharmaceuticals produced in Chinese hamster ovary cells or any of the study drugs
  • Active bacterial, viral, fungal, or other infection or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1
  • Positive test results for chronic infection (defined as positive HBsAg serology)
  • Positive test results for (hepatitis C virus [HCV] antibody serology testing)
  • Known history of positive status
  • History of progressive multifocal leukoencephalopathy (PML)
  • Vaccination with a within 28 days prior to Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study
  • History of prior other with the exception of: a. Curatively treated carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal- or squamous-cell skin cancer, Stage I melanoma, or low-grade, early-stage localized prostate cancer b. Any previously treated malignancy that has been in remission without treatment for ≥ 2 years prior to enrollment
  • Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
  • Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1, Day 1, or anticipation of a major surgical procedure during the course of the study
  • Any of the following abnormal laboratory values:

    1. Creatinine > 1.5 × the (ULN) (unless normal) or creatinine clearance \< 40 mL/min
    2. (AST) or alanine aminotransferase (ALT) > 2.5 × ULN
    3. Total ≥ 1.5 × the ULN: Patients with documented Gilbert disease may be enrolled if total bilirubin is ≤ 3.0 × the ULN.
    4. (INR) > 1.5 in the absence of therapeutic anticoagulation
    5. Partial thromboplastin time or activated partial thromboplastin time > 1.5 × ULN in the absence of a lupus anticoagulant
  • For patients who will be receiving CHOP: (LVEF) \< 50% by multigated acquisition (MUGA) scan or echocardiogram
  • Pregnant or lactating, or intending to become pregnant during the study
  • Any therapy within 28 days prior to the start of Cycle 1
  • Positive test results for human T-lymphotropic virus 1 (HTLV-1)
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Obinutuzumab+Chemotherapy

    Participants received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \[CVP - 21-day cycle\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator is free to choose the chemotherapy for each patient. Obinutuzumab and chemotherapy is administered during induction phase and obinutuzumab monotherapy is administered during maintenance phase.

    Drug: Obinutuzumab · Drug: Bendamustine · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone/Prednisolone/Methylprednisolone · Drug: Vincristine

Interventions

  • Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).

    Also known as: GA101, RO5072759

  • Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.

  • Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

  • Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.

  • DrugPrednisone/Prednisolone/Methylprednisolone

    Drug pages: Prednisone · Prednisolone · Methylprednisolone

    Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

  • Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

06

What researchers measure

Primary outcomes

  1. Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR

    IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator.

    Time frame: Within 24 hours from the end of study treatment infusion of Day 1 in Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected)

Secondary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product, regardless of causal attribution. An AE was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study, recurrence of an intermittent medical condition, deterioration in a laboratory value or other clinical test or were related to a protocol-mandated intervention were also considered AEs. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

    Time frame: Baseline up to end of study (approximately 4 years)

  2. Percentage of IRRs Regardless of Grade by Cycle

    IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator.

    Time frame: Within 24 hours from the end of study treatment infusion in all cycles, including maintenance ((1 cycle: 21 or 28 days depending on the chemotherapy selected); up to approximately 2.5 years)

  3. Time to IRR From Infusion to Onset of the IRR During Cycle 2

    Time to IRR (of any grade) in Cycle 2 was defined as the time from the start of infusion (i.e., start date/time of infusion of the first component of study treatment) in Cycle 2 to the onset of the IRR (of any grade) during Cycle 2.

    Time frame: From infusion to onset of IRR during Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected)

  4. Duration (In Minutes) of Obinutuzumab Administration by Cycle

    The duration of obinutuzumab administration (in minutes) by cycle was defined as the difference between the end time and the start time of obinutuzumab administration.

    Time frame: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)

  5. Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle

    Time frame: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)

  6. Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle

    The duration, in minutes, of IRRs during all cycles, where obinutuzumab was administered as an SDI.

    Time frame: All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)

  7. Objective Response Rate (ORR) at the End of Induction (EOI) Therapy

    ORR at EOI therapy was defined as the percentage of particpants with either a CR, CR unconfirmed or PR at the EOI visit, as determined by the investigator and according to the guidelines used at the site.

    Time frame: Baseline up to end of induction therapy (up to approximately 6 months)

  8. Progression-Free Survival (PFS) Rate at the End of the Study

    PFS was defined as the time from start of treatment to the first occurrence of disease progression as assessed by the investigator according to the guidelines used at the site or death from any cause.

    Time frame: Baseline up to end of study (up to approximately 4 years)

  9. Overall Survival (OS) at the End of the Study

    OS was defined as the time from start of treatment (date of first intake of any study treatment component) to death from any cause.

    Time frame: Baseline up to end of study (up to approximately 4 years)

  10. Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site

    The CR30 rate was defined as the percentage of participants with a CR at 30 months from study treatment initiation (date of first intake of any study treatment component), as determined by the investigator according to the guidelines used at the site.

    Time frame: Baseline up to 30 months

07

Results

Posted Aug 24, 2021

Participant flow

Participants were enrolled at 35 sites across 7 countries.

Induction Phase
Participant flow — Induction Phase
MilestoneAll ParticipantsMaintenanceFollow-up
Started11300
Completed9300
Not completed2000
Withdrew: Adverse event500
Withdrew: Measures due to covid19; transformation to double hit high-grade b lymphoma; discontinuation of trt.300
Withdrew: Physician decision200
Withdrew: Progressive disease600
Withdrew: Withdrawal by subject400
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneAll ParticipantsMaintenanceFollow-up
Started0950
Completed0670
Not completed0280
Withdrew: Adverse event080
Withdrew: Death050
Withdrew: Progressive disease070
Withdrew: Withdrawal by subject020
Withdrew: Physician decision010
Withdrew: Various reasons040
Withdrew: Protocol deviation010
Follow-up Phase
Participant flow — Follow-up Phase
MilestoneAll ParticipantsMaintenanceFollow-up
Started0099
Completed0092
Not completed007
Withdrew: Adverse event002
Withdrew: Death001
Withdrew: Progressive disease003
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPercentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR

IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator.

Time frame:
Within 24 hours from the end of study treatment infusion of Day 1 in Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected)
Reported as:
Number · Percentage of Participants
Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR
Percentage of ParticipantsAll Participants
Percentage of Grade >=3 Infusion-Related Reactions (IRRs) During Cycle 2 in Patients Who Had Previously Received Obinutuzumab at the Standard Infusion Rate During Cycle 1 Without Experiencing a Grade 3 or 4 IRR0 (0.00 to 3.66)
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product, regardless of causal attribution. An AE was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study, recurrence of an intermittent medical condition, deterioration in a laboratory value or other clinical test or were related to a protocol-mandated intervention were also considered AEs. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

Time frame:
Baseline up to end of study (approximately 4 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsAll ParticipantsMaintenance: ObinutuzumabFollow-up
Percentage of Participants With Adverse Events (AEs)99.190.527.3
SecondaryPercentage of IRRs Regardless of Grade by Cycle

IRRs were defined as all adverse events (AEs) that occurred during or within 24 hours from the end of study treatment infusion and were judged as related to infusion of study treatment components by the investigator.

Time frame:
Within 24 hours from the end of study treatment infusion in all cycles, including maintenance ((1 cycle: 21 or 28 days depending on the chemotherapy selected); up to approximately 2.5 years)
Reported as:
Number · Percentage of Participants
Percentage of IRRs Regardless of Grade by Cycle
Percentage of ParticipantsAll Participants
Cycle 1 Day 150.4
Cycle 1 Day 27.8
Cycle 1 Day 85.4
Cycle 1 Day 154.5
Cycle 211.8
Cycle 38.3
Cycle 46.5
Cycle 55.6
Cycle 64.8
Cycle 73.6
SecondaryTime to IRR From Infusion to Onset of the IRR During Cycle 2

Time to IRR (of any grade) in Cycle 2 was defined as the time from the start of infusion (i.e., start date/time of infusion of the first component of study treatment) in Cycle 2 to the onset of the IRR (of any grade) during Cycle 2.

Time frame:
From infusion to onset of IRR during Cycle 2 (1 cycle: 21 or 28 days depending on the chemotherapy selected)
Reported as:
Mean · Hours
Time to IRR From Infusion to Onset of the IRR During Cycle 2
HoursAll Participants
Time to IRR From Infusion to Onset of the IRR During Cycle 211.800 ± NA
SecondaryDuration (In Minutes) of Obinutuzumab Administration by Cycle

The duration of obinutuzumab administration (in minutes) by cycle was defined as the difference between the end time and the start time of obinutuzumab administration.

Time frame:
All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)
Reported as:
Mean · Minutes
Duration (In Minutes) of Obinutuzumab Administration by Cycle
MinutesAll Participants
Cycle(C) 1 Day(D) 1295.96 ± 147.87
C1D8215.97 ± 46.99
C1D15208.91 ± 33.13
C299.61 ± 13.36
C3103.29 ± 65.45
C499.26 ± 13.90
C598.46 ± 16.48
C699.10 ± 12.18
C798.84 ± 13.61
C895.68 ± 4.12
Maintenance Week 197.64 ± 10.08
Maintenance Week 996.78 ± 8.49
Maintenance Week 1797.77 ± 7.66
Maintenance Week 2597.16 ± 7.23
Maintenance Week 3395.08 ± 4.27
Maintenance Week 4195.77 ± 5.26
Maintenance Week 4993.56 ± 4.48
Maintenance Week 5793.50 ± 4.95
SecondaryType of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
Time frame:
All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)
Reported as:
Number · Percentage of Participants
Type of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
Percentage of ParticipantsAll Participants
Cycle (C) 5- Hypertension33.3
C5 - Renal failure33.3
C5 - Weight increased33.3
SecondaryDuration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle

The duration, in minutes, of IRRs during all cycles, where obinutuzumab was administered as an SDI.

Time frame:
All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)
Reported as:
Mean · Minutes
Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle
MinutesAll Participants
Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle165.0 ± NA
SecondaryObjective Response Rate (ORR) at the End of Induction (EOI) Therapy

ORR at EOI therapy was defined as the percentage of particpants with either a CR, CR unconfirmed or PR at the EOI visit, as determined by the investigator and according to the guidelines used at the site.

Time frame:
Baseline up to end of induction therapy (up to approximately 6 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) at the End of Induction (EOI) Therapy
Percentage of ParticipantsAll Participants
Complete Response68.1
Partial Response19.5
SecondaryProgression-Free Survival (PFS) Rate at the End of the Study

PFS was defined as the time from start of treatment to the first occurrence of disease progression as assessed by the investigator according to the guidelines used at the site or death from any cause.

Time frame:
Baseline up to end of study (up to approximately 4 years)
Reported as:
Median · Months
Progression-Free Survival (PFS) Rate at the End of the Study
MonthsAll Participants
Progression-Free Survival (PFS) Rate at the End of the Study33.97 (32.13 to NA)
SecondaryOverall Survival (OS) at the End of the Study

OS was defined as the time from start of treatment (date of first intake of any study treatment component) to death from any cause.

Time frame:
Baseline up to end of study (up to approximately 4 years)
Reported as:
Median · Months
Overall Survival (OS) at the End of the Study
MonthsAll Participants
Overall Survival (OS) at the End of the StudyNA (33.97 to NA)
SecondaryComplete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site

The CR30 rate was defined as the percentage of participants with a CR at 30 months from study treatment initiation (date of first intake of any study treatment component), as determined by the investigator according to the guidelines used at the site.

Time frame:
Baseline up to 30 months
Reported as:
Number · Percentage of Participants
Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site
Percentage of ParticipantsAll Participants
Complete Response (CR) Rate at 30 Months (CR30), as Assessed by the Investigator and According to the Guidelines Used at the Site55.6 (45.68 to 65.12)

Adverse events

Collected over Baseline up to end of study (approximately 4 years). Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants9/113 (8%)21/113 (18.6%)111/113 (98.2%)
Maintenance8/95 (8.4%)17/95 (17.9%)76/95 (80%)
Follow-up4/99 (4%)11/99 (11.1%)13/99 (13.1%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventAll ParticipantsMaintenanceFollow-up
Febrile neutropeniaBlood and lymphatic system disorders5/1131/950/99
COVID-19 pneumoniaInfections and infestations0/1134/953/99
COVID-19Infections and infestations1/1131/954/99
PneumoniaInfections and infestations3/1132/951/99
Pulmonary sepsisInfections and infestations0/1132/950/99
SepsisInfections and infestations0/1132/950/99
NeutropeniaBlood and lymphatic system disorders2/1131/950/99
Pneumonia streptococcalInfections and infestations0/1131/950/99
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1131/950/99
ThyroiditisEndocrine disorders0/1131/950/99
Most frequent other events
Showing 10 of 56
Most frequent other events
EventAll ParticipantsMaintenanceFollow-up
Infusion related reactionInjury, poisoning and procedural complications69/1133/950/99
NeutropeniaBlood and lymphatic system disorders68/11316/952/99
NauseaGastrointestinal disorders48/1134/950/99
ConstipationGastrointestinal disorders39/1136/950/99
LymphopeniaBlood and lymphatic system disorders22/1134/950/99
AnaemiaBlood and lymphatic system disorders20/1133/951/99
LeukopeniaBlood and lymphatic system disorders20/1133/950/99
ThrombocytopeniaBlood and lymphatic system disorders20/1134/951/99
Neuropathy peripheralNervous system disorders19/1133/950/99
InsomniaPsychiatric disorders19/1135/951/99

Baseline characteristics

The all participants population includes all enrolled participants.

Age, Continuous
Age, Continuous(Years)All Participants
Mean58.9 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female56
Male57
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Asian27
White82
Other2
Multiple2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Hispanic or Latino33
Not Hispanic or Latino80
08

Study locations

33 sites
  • Rocky Mountain Cancer Center; Medical Oncology
    Boulder, Colorado 80303, United States
  • American Oncology Partners of Maryland, PA
    Bethesda, Maryland 20817-1915, United States
  • Summit Medical Center
    Florham Park, New Jersey 07932, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Willamette Valley Cancer Ctr - 520 Country Club
    Eugene, Oregon 97401-8122, United States
  • Texas Onc-Central Austin CA Ct
    Austin, Texas 78731, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • NOHC - Núcleo de Oncologia e Hematologia do Ceará
    Fortaleza, CE 60115-281, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-903, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-120, Brazil
  • Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie
    Chemnitz, 09113, Germany
  • Städtisches Klinikum Dessau
    Dessau-Roßlau, 06847, Germany
  • Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie
    Frankfurt, 60596, Germany
  • OncoResearch Lerchenfeld GmbH
    Hamburg, 22081, Germany
  • Klinik der Uni zu Köln; I. Med. Klinik
    Köln, 50937, Germany
  • MVZ Dr. Vehling-Kaiser GmbH; Onkologische Praxis
    Landshut, 84036, Germany
  • Onkologische Schwerpunktpraxis Lübeck
    Lübeck, 23562, Germany
  • Chiba Cancer Center
    Chiba, 260-8717, Japan
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • Kobe City Medical Center General Hospital
    Hyogo, 650-0047, Japan
  • Kindai University Hospital
    Osaka, 589-8511, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • The Cancer Institute Hospital of JFCR
    Tokyo, 135-8550, Japan
  • Albert Schweitzer Ziekenhuis - loc Dordrecht
    Dordrecht, 3318 AT, Netherlands
  • Martini Ziekenhuis
    Groningen, 9728 NT, Netherlands
  • Hospital De Txagorritxu; Servicio de Hematologia
    Vitoria, Alava 01009, Spain
  • Hospital Universitario Puerta del Mar; Servicio de Hematologia
    Cádiz, Cadiz 11009, Spain
  • Hospital del Mar; Servicio de Hematologia
    Barcelona, 08003, Spain
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología
    Murcia, 30008, Spain
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital
    Portsmouth, PO6 3LY, United Kingdom
  • Royal Cornwall Hospital
    Truro, TR1 3LQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Aug 2020, 17 months.

Results were first posted in Aug 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2019
First posted
Jan 28, 2019
StartActual
Feb 26, 2019
Primary completionActual
Aug 4, 2020
CompletionActual
Jan 25, 2023
Results first posted
Aug 24, 2021
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03817853
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Feb 26, 2019
Primary completion
Aug 4, 2020
Completion
Jan 25, 2023
Results posted
Aug 24, 2021
Last update
Apr 4, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion